CN107235914A - A kind of drug hydrate for the treatment of cancer and preparation method thereof - Google Patents
A kind of drug hydrate for the treatment of cancer and preparation method thereof Download PDFInfo
- Publication number
- CN107235914A CN107235914A CN201710424797.1A CN201710424797A CN107235914A CN 107235914 A CN107235914 A CN 107235914A CN 201710424797 A CN201710424797 A CN 201710424797A CN 107235914 A CN107235914 A CN 107235914A
- Authority
- CN
- China
- Prior art keywords
- olaparib
- preparation
- cancer
- tetramethylethylenediamine
- trihydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to pharmaceutical technology field, a kind of drug hydrate for the treatment of cancer and preparation method thereof is disclosed, specifically, the invention discloses a kind of olaparib trihydrate and preparation method thereof.The X ray powder diffractions that olaparib trihydrate disclosed by the invention is represented with the 2 θ ± 0.2 ° angles of diffraction show characteristic diffraction peak at 6.3928 °, 6.9115 °, 12.6931 °, 15.1126 °, 15.9045 °, 17.7123 °, 19.2086 °, 19.7743 °, 20.2325 °, 21.0346 °, 22.2218 °, 29.0633 °, 30.4218 °, the X ray powder diffractograms obtained using Cu K alpha ray measurements are as shown in figure 1, entirely different with prior art.Surprisingly find that the olaparib trihydrate dissolubility that the present invention is obtained is significantly improved through experiment.The invention also discloses the preparation method of olaparib trihydrate, the preparation method is simple to operation, and yield and purity are high, and reaction condition is gentle, are adapted to large-scale production.The capsule dissolubility and stability that the olaparib trihydrate of the present invention is made are significantly improved, and are especially suitable for clinical practice.
Description
Technical field
The invention belongs to pharmaceutical technology field, a kind of drug hydrate for the treatment of cancer and preparation method thereof is disclosed, is had
Body is related to a kind of olaparib trihydrate and preparation method thereof.
Background technology
Olaparib, chemical entitled 4- [3- (4- cyclopropane carbonyl piperazine -1- carbonyls) -4- luorobenzyls] -2H- phthalazines -1-
Ketone, English entitled Olaparib, structural formula is as shown in Equation 1：
Olaparib (Olaparib) is the KuDOS drugmakers of wholly-owned subsidiary by AstraZeneca (AstraZeneca)
A kind of small molecule of research and development, is a kind of potent PARP inhibitors, and it promotes tumour by suppressing DNA of tumor cell injury repair
Apoptosis, so as to strengthen the curative effect of radiotherapy and alkylating agent and platinum-based chemotherapy, is mainly used in treating mastocarcinoma gene
The gene mutation cancer (being primarily present in breast cancer, oophoroma and prostate cancer) of No. one or No. two (BRCA-1 or BRCA-2).It is difficult to understand
La Pani can selectivity act on tumour cell, normal cell is due to remaining double-strand repair function without destroyed.Cancer
Cell is all lacked or is mutated due to two allele, and double-strand repair function is lost, and cell is finally dead, this new medicine
Treatment to refractory neoplasm brings hope.
CN101528714A discloses the crystal formation A of the solvent-free compound of olaparib, and its X-ray powder diffraction figure (2 θ) exists
12.0 °, 17.8 °, 21.1 °, 22.3 °, 29.2 °, 10.5 °, 14.0 °, 21.7 °, 24.3 °, 26.1 ° of existing characteristics peaks, DSC are shown
There is endothermic peak at 210.1 DEG C ± 1 DEG C, the stability of crystal form is good, it is without hydrate after testing.
The A of patent CN 105439961 disclose crystal formation I of olaparib and preparation method thereof, the crystal formation that the present invention is provided
I, it is characterised in that its X-ray powder diffraction figure is 6.4 ° ± 0.2 °, 12.7 ° ± 0.2 °, 15.1 ° ± 0.2 ° in 2theta values
Place has characteristic peak, after testing its crystallization water for containing 1.5 molecules.Its preparation method is：The solid of olaparib is placed in pure
Stirring is obtained in water or aqueous solvent, the aqueous solvent, including aqueous volume is not less than 80% mixed solvent, described aqueous
Solvent, including alcohols, ketone, ethers, alkanes, aromatic solvents.The stability of crystal form is than in patent CN101528714A
Crystal formation A more preferably, can keep stable during preparation, storage and formulation development, will not occur to turn crystalline substance；Solubility, draw
Moist to meet medicinal requirements, and preparation method solvent for use asepsis environment-protecting, optimization and exploitation to the future medicine have important
Value, a preferably selection is provided for pharmaceutical solid preparation.
The A of patent CN 105254572 disclose a kind of crystal formation of olaparib and preparation method thereof, are radiated using CuK α,
The powder x-ray diffraction represented with 2 θ angles 22.9 ± 0.5,23.4 ± 0.5,21.0 ± 0.5,17.1 ± 0.5,17.3 ±
0.5,14.2 ± 0.5,15.0 ± 0.5,13.5 ± 0.5,18.6 ± 0.5,20.6 ± 0.5,10.2 ± 0.5,20.3 ± 0.5,
21.9 ± 0.5,25.8 ± 0.5,26.5 ± 0.5 have diffraction maximum, and it is without hydrate after testing.It is shown as when heating rate is
There is 1 endothermic peak in 10 DEG C per minute of DSC collection of illustrative plates at 175.3 DEG C ± 1 DEG C.Present invention also offers olaparib crystal formation
Preparation method, including：1) olaparib is mixed into backflow with solvent, obtains olaparib solution, the solvent be normal propyl alcohol,
One or more in isopropanol, n-butanol, isobutanol and the tert-butyl alcohol；2) olaparib solution is filtered, natural cooling is obtained
Described olaparib crystal formation.The granularity for the crystal formation olaparib that the present invention is provided is small, and dissolution rate is fast.Crystalline substance of the present invention
The granularity of type olaparib is that D50 is 2.45 microns, and granularity is smaller, and then when causing it as preparation, dissolution rate is fast, improves
The drug effect of product；And the preparation method that the present invention is provided is simple, obtained crystal formation olaparib performance is also stablized.
CN101821242A discloses the crystal formation L of the solvent-free compound of olaparib, and its X-ray powder diffraction figure (2 θ) exists
14.4 °, 17.2 °, 17.5 °, 18.8 °, 23.0 °, 10.4 °, 13.6 °, 25.1 ° of existing characteristics peaks, DSC are shown in 198.5 DEG C ± 1
DEG C there is endothermic peak, the stability of crystal form is good, it is without hydrate after testing.
CN106554315A discloses a kind of olaparib monohydrate, and its X-ray powder diffraction figure (2 θ) exists
5.620°、6.420°、7.420°、9.340°、10.120°、11.240°、14.020°、16.880°、17.540°、18.120°、
20.200 °, 22.460 °, 24.180 °, 26.720 °, 30.200 °, 33.100 °, 34.640 °, 37.340 °, 39.420 ° have spy
Peak is levied, its preparation method is that olaparib adds 4-5 times of weight/volume acetone-water=3-4:In 2-1 mixed liquor, heating
To 70-75 DEG C, filter while hot, filtrate naturally cools to room temperature, then is incubated 5-10 hours, separate out crystallization, filtering, through dry
Arrive.The crystal of the present invention has the advantage that：Purity is high, and stability is good, is increased weight even if moisture absorption under high humidity conditions also unobvious.
Olaparib belongs to insoluble drug, is usually prepared into solid pharmaceutical preparation administration, and for the solid system of crystal formation medicine
For agent, the stability and dissolution rate of preparation and the crystal formation of bulk drug have very big relation, olaparib in crystallization, if
Using different solvent and process conditions, then its molecule differs in the number of permutations of each crystal formation structure cell and position and latticed form
Sample, forms different crystal structures, and the polymorphous change of olaparib can change its property, quality and drug effect.Therefore, Aura handkerchief
The stable crystalline of Buddhist nun, the physicochemical properties for further studying the compound study its drug regimen and clinical practice, tool
It is of great significance.
Compound polymorphic is a kind of universal phenomenon, for premium properties one such as the stability, hygroscopicity, dissolubility of crystal formation
It is directly a kind of long-range pursuit.Invention finds by substantial amounts of experimental study, and most of existing crystal formation is from stability, hygroscopicity solution
The certainly stable problem of its preparation, and the dissolution of preparation then often passes through the addition and the control of raw material crystal formation of auxiliary material in production process
System is angularly solved.The slightly solubility of olaparib raw material is always the technological difficulties of this area, can not be broken through always.
The present invention passes through substantial amounts of experimental study, using new method for crystallising, has obtained a kind of new olaparib crystal formation,
It is trihydrate after testing, and the olaparib trihydrate purity that the present invention is provided is high, stability is good, is surprisingly sent out through experiment
The olaparib trihydrate dissolubility that the existing present invention is obtained is significantly improved.The invention also discloses olaparib trihydrate
Preparation method, the preparation method is simple to operation, and reaction condition is gentle, and yield and purity are high, are adapted to large-scale production.The present invention
The capsule dissolubility that is made of olaparib trihydrate and stability significantly improve, be especially suitable for clinical practice.
The content of the invention
The present invention is intended to provide a kind of olaparib trihydrate and preparation method thereof, technical problem to be solved is to carry
Dissolubility and purity of the high olaparib in water, so that the dissolution rate and bioavilability of its preparation are improved, it is existing to overcome
Technological deficiency.
In order to realize the purpose of the present invention, the technical scheme used for：
A kind of drug hydrate for the treatment of cancer, the hydrate is olaparib trihydrate, and its molecular formula is：
C24H23FN4O3·3H2O, structural formula is following (Formula II), and its X-ray powder diffraction collection represented with the 2 θ ± 0.2 ° angles of diffraction exists
6.3928°、6.9115°、12.6931°、15.1126°、15.9045°、17.7123°、19.2086°、19.7743°、
Characteristic diffraction peak is shown at 20.2325 °, 21.0346 °, 22.2218 °, 29.0633 °, 30.4218 °.
The X-ray powder diffraction figure that the olaparib trihydrate that the present invention is provided is obtained using Cu-K alpha ray measurements is such as
Shown in Fig. 1.
Present invention also offers a kind of preparation method of olaparib trihydrate, concretely comprise the following steps：
(1) olaparib crude product is taken, the mixed solution of tetramethylethylenediamine/water is added, heating stirring dissolving 1-2min lives
Property carbon decoloring, suction filtration；
(2) step (1) filtrate is down to -2 DEG C, the tetramethylethylenediamine of precooling is added dropwise, continue the crystallization that cools；
(3) insulated and stirred is complete to crystallization, growing the grain, and suction filtration is washed, and is dried, is obtained white crystalline powder.
Preferably, in tetramethylethylenediamine/water mixed solution described in step (1), the volume of tetramethylethylenediamine and water
Than for 25:1.0~1.2；The mass volume ratio of step (1) the olaparib crude product and mixed solution is 1g:10ml~12ml；
Described mixing speed is 30-50 revs/min.
It is further preferred that in tetramethylethylenediamine/water mixed solution described in step (1), tetramethylethylenediamine and water
Volume ratio be 25:1.1；The mass volume ratio of step (1) the olaparib crude product and mixed solution is 1g:11ml；It is described
Mixing speed be 40 revs/min.
Preferably, the volume ratio 0.5~1 of step (2) tetramethylethylenediamine and step (1) mixed solution:1；Step
(2) rate of addition be 1.0~2.0mL/min, cooling extent be every 10 minutes 1 DEG C~3 DEG C；Step (2) the cooling analysis
Crystalline substance is to be cooled to -10 DEG C~-8 DEG C crystallizations.
It is further preferred that the volume ratio 0.8 of step (2) tetramethylethylenediamine and step (1) mixed solution:1；Step
Suddenly (2) described rate of addition be 1.5mL/min, cooling extent be every 10 minutes 2 DEG C；Step (2) the cooling crystallization is cooling
To -9 DEG C of crystallizations.
Preferably, step (3) described rearing crystal time is 1h~3h；Step (3) described drying temperature is 40 DEG C~50 DEG C.
It is further preferred that step (3) described rearing crystal time is 2h；Step (3) described drying temperature is 45 DEG C.
In the present invention, described olaparib crude product can be olaparib solid mixture Aura to be further purified
Handkerchief Buddhist nun crude product can also be marketable material or be prepared by art methods that the crystal formation result of gained is in error range
It is interior, it is novel crystal forms of the present invention.
Present invention also offers a kind of pharmaceutical composition containing olaparib trihydrate of the present invention, the pharmaceutical composition
For the capsule containing olaparib trihydrate.
The formation mechenism of crystal is very complicated, and the acquisition of a new crystal also has very big contingency, and sometimes different is molten
Agent, identical crystal structure can be produced under different crystallization conditions.Some specific crystal formations also can not necessarily obtain more added with
The physicochemical property of profit.The properties such as stability, hygroscopicity, dissolubility, bioactivity, the toxicity of medicine can be produced because of the difference of crystal formation
Raw huge difference.
The present invention passes through substantial amounts of experiment sieving, by selecting different solvents to dissolve and different solvent crystallizations, obtains
The preparation method of the present invention, by the control to mixing speed, solvent load, temperature and rearing crystal time, is unexpectedly obtained
A kind of olaparib novel crystal forms, it is trihydrate after testing.Aura handkerchief trihydrate Buddhist nun purity that the present invention is provided is high, stably
Property it is good, surprisingly find that the obtained olaparib trihydrate dissolubility of the present invention is significantly improved through experiment.Invention additionally discloses
The preparation method of olaparib trihydrate, the preparation method is simple to operation, and reaction condition is gentle, is adapted to extensive raw
Production.The capsule dissolubility and stability that the olaparib trihydrate of the present invention is made are significantly improved, and are especially suitable for clinical practice.
Research shows that in the X-ray powder diffraction pattern, the diffraction spectrogram obtained by novel crystal forms is for specific crystal formation
Often characteristic, the wherein relative intensities of bands of a spectrum (especially in low angle) may because of crystallization condition, particle diameter and its
The difference of its condition determination and the advantage orientation effect that produces and change.Therefore, the relative intensity of diffraction maximum is to targeted crystalline substance
Type is not characteristic, when judging whether identical with known crystal formation, it should be noted that the relative position at peak rather than
Their relative intensity.
Olaparib trihydrate crystal provided by the present invention confirms the crystallization water containing three molecules, and its character is white
Crystalline powder, the loss that the crystallization water will not occur under the conditions of air drying.And its powder x-ray diffraction collection of illustrative plates with it is existing
Technology has the relative position at visibly different peak, it is seen that it is a kind of novel crystal forms unlike the prior art.
Carry out the explanation and illustration present invention below by being studied the olaparib trihydrate crystal formation that the present invention is provided
Technical scheme：
1st, elementary analysis C24H23FN4O3·3H2O
Instrument：VarioELcube elemental analysers；It is C, H, O, N to measure element；
DIOENXDX-500 type ion chromatographs；Measurement element is F.
Elementary analysis (%) theoretical value：H (5.98), C (59.01), N (11.47), O (19.65), F (3.89).
Elementary analysis (%) measured value is：H (5.99), C (59.02), N (11.45), O (19.64), F (3.90).
It is consistent substantially with the theoretical value of elementary analysis.
2nd, crystal formation is detected
The olaparib trihydrate for taking the present invention to prepare, the X-ray powder obtained using Cu-K alpha ray measurements
Diffraction pattern as shown in figure 1, its X-ray powder diffraction figure for being represented with the angles of diffraction of 2 θ ± 0.2 6.3928 °, 6.9115 °,
12.6931°、15.1126°、15.9045°、17.7123°、19.2086°、19.7743°、20.2325°、21.0346°、
Characteristic peak is shown at 22.2218 °, 29.0633 °, 30.4218 °.
3rd, differential thermal analysis and thermogravimetric analysis
Thermogravimetric and differential thermal analysis are carried out to olaparib trihydrate prepared by the present invention, as a result such as accompanying drawing 2 and the institute of accompanying drawing 3
Show；As a result show, this product is in 100 DEG C or so the quick weight for losing about 3 hydrones；This product has endothermic peak at about 210 DEG C,
It is demonstrated for a kind of different crystal formation from side.
4th, water analysis
Determined using cassette moisture teller, the water content of olaparib trihydrate of the invention is 11.06-
11.08%, it is consistent with the theoretical water content 11.06% of trihydrate, it was demonstrated that the present invention contains the crystallization water of 3 molecules.
5th, purity detecting
Through HPLC purity detectings, the purity of the olaparib trihydrate that the present invention is prepared can reach 99.97~
99.99%.
6th, fusing point is detected
The olaparib trihydrate for taking the present invention to prepare is detected that fusing point is 209~211 DEG C.
Compared with prior art, the invention has the advantages that：
(1) olaparib trihydrate provided by the present invention is a kind of novel crystal forms different from prior art；The present invention
The preparation method of the olaparib trihydrate provided is simple to operation, and reaction condition is gentle, and yield is more than 99.8%, purity
Height, is adapted to large-scale production.
(2) the olaparib trihydrate purity height of the invention provided, stability are good, and the present invention is surprisingly found through experiment
Obtained olaparib trihydrate dissolubility is significantly improved.The capsule dissolubility that the olaparib trihydrate of the present invention is made
And stability is significantly improved, clinical practice is especially suitable for.
Brief description of the drawings
The X-ray powder diffraction collection for the olaparib trihydrate that Fig. 1 is prepared for the present invention.
Fig. 2 is the thermogravimetric analysis TGA collection of illustrative plates of olaparib trihydrate prepared by the embodiment of the present invention 1.
Fig. 3 is the DSC collection of illustrative plates of olaparib trihydrate prepared by the embodiment of the present invention 1.
Specific embodiment
Technical scheme is described in detail with embodiment below, it will help to technical scheme
Advantage, effect have and further understand, embodiment does not limit protection scope of the present invention, and protection scope of the present invention is by weighing
Profit requires to determine.
Embodiment 1：The preparation of olaparib trihydrate
(1) olaparib crude product 100g is taken, adding tetramethylethylenediamine/water, (volume ratio is 25:1.0) mixed solution
1000ml, (30 revs/min) dissolving 1-2min of heating stirring, activated carbon decolorizing, suction filtration；
(2) step (1) filtrate is down to -2 DEG C with every 10 minutes 1 DEG C of speed, precooling is added dropwise with 1.0mL/min speed
Tetramethylethylenediamine 500ml, continuation -10 DEG C of crystallizations are cooled to every 10 minutes 1 DEG C of speed；
(3) insulated and stirred is complete to crystallization, and growing the grain 1h, suction filtration, washing, 40 DEG C of dryings obtain white crystalline powder
99.90g, yield 99.90%, purity 99.98%.
The X-ray powder diffraction spectrogram that obtained white crystalline powder is obtained using Cu-K alpha ray measurements is shown in Fig. 1.
Embodiment 2：The preparation of olaparib trihydrate
(1) olaparib crude product 100g is taken, adding tetramethylethylenediamine/water, (volume ratio is 25:1.2) mixed solution
1200ml, (50 revs/min) dissolving 1-2min of heating stirring, activated carbon decolorizing, suction filtration；
(2) step (1) filtrate is down to -2 DEG C with every 10 minutes 3 DEG C of speed, precooling is added dropwise with 2.0mL/min speed
Tetramethylethylenediamine 1200ml, continuation -10 DEG C of crystallizations are cooled to every 10 minutes 3 DEG C of speed；
(3) insulated and stirred is complete to crystallization, and growing the grain 3h, suction filtration, washing, 50 DEG C of dryings obtain white crystalline powder
99.89g, yield 99.89%, purity 99.97%.
The X-ray powder diffraction spectrogram that obtained white crystalline powder is obtained using Cu-K alpha ray measurements is with implementing
Example 1 is similar.
Embodiment 3：The preparation of olaparib trihydrate
(1) olaparib crude product 100g is taken, adding tetramethylethylenediamine/water, (volume ratio is 25:1.1) mixed solution
1100ml, (40 revs/min) dissolving 1-2min of heating stirring, activated carbon decolorizing, suction filtration；
(2) step (1) filtrate is down to -2 DEG C with every 10 minutes 2 DEG C of speed, precooling is added dropwise with 1.5mL/min speed
Tetramethylethylenediamine 880ml, continuation -9 DEG C of crystallizations are cooled to every 10 minutes 2 DEG C of speed；
(3) insulated and stirred is complete to crystallization, and growing the grain 2h, suction filtration, washing, 45 DEG C of dryings obtain white crystalline powder
99.95g, yield 99.95%, purity 99.99%.
The X-ray powder diffraction spectrogram that obtained white crystalline powder is obtained using Cu-K alpha ray measurements is with implementing
Example 1 is similar.
Embodiment 4：The preparation of olaparib trihydrate
(1) olaparib crude product 100g is taken, adding tetramethylethylenediamine/water, (volume ratio is 25:1.1) mixed solution
1200ml, (40 revs/min) dissolving 1-2min of heating stirring, activated carbon decolorizing, suction filtration；
(2) step (1) filtrate is down to -2 DEG C with every 10 minutes 1 DEG C of speed, precooling is added dropwise with 1.0mL/min speed
Tetramethylethylenediamine 960ml, continuation -8 DEG C of crystallizations are cooled to every 10 minutes 2 DEG C of speed；
(3) insulated and stirred is complete to crystallization, and growing the grain 2h, suction filtration, washing, 45 DEG C of dryings obtain white crystalline powder
99.92g, yield 99.92%, purity 99.98%.
The X-ray powder diffraction spectrogram that obtained white crystalline powder is obtained using Cu-K alpha ray measurements is with implementing
Example 1 is similar.
Embodiment 5：The preparation of olaparib trihydrate
(1) olaparib crude product 100g is taken, adding tetramethylethylenediamine/water, (volume ratio is 25:1.0) mixed solution
1000ml, (50 revs/min) dissolving 1-2min of heating stirring, activated carbon decolorizing, suction filtration；
(2) step (1) filtrate is down to -2 DEG C with every 10 minutes 1 DEG C of speed, precooling is added dropwise with 1.5mL/min speed
Tetramethylethylenediamine 1000ml, continuation -10 DEG C of crystallizations are cooled to every 10 minutes 3 DEG C of speed；
(3) insulated and stirred is complete to crystallization, and growing the grain 3h, suction filtration, washing, 50 DEG C of dryings obtain white crystalline powder
99.93g, yield 99.93%, purity 99.99%.
The X-ray powder diffraction spectrogram that obtained white crystalline powder is obtained using Cu-K alpha ray measurements is with implementing
Example 1 is similar.
Embodiment 6：The preparation of olaparib trihydrate
(1) olaparib crude product 100g is taken, adding tetramethylethylenediamine/water, (volume ratio is 25:1.2) mixed solution
1200ml, (30 revs/min) dissolving 1-2min of heating stirring, activated carbon decolorizing, suction filtration；
(2) step (1) filtrate is down to -2 DEG C with every 10 minutes 3 DEG C of speed, precooling is added dropwise with 2.0mL/min speed
Tetramethylethylenediamine 1200ml, continuation -9 DEG C of crystallizations are cooled to every 10 minutes 2 DEG C of speed；
(3) insulated and stirred is complete to crystallization, and growing the grain 1h, suction filtration, washing, 45 DEG C of dryings obtain white crystalline powder
99.92g, yield 99.92%, purity 99.98%.
The X-ray powder diffraction spectrogram that obtained white crystalline powder is obtained using Cu-K alpha ray measurements is with implementing
Example 1 is similar.
The present invention is further illustrated below by experimental example：
Experimental example 1：Solvent screening is tested
Operated using the preparation method of the present invention, it is specific as follows：
(1) take olaparib crude product 100g, add 1000ml solvent orange 2 As/solvent B mixed solution, heating stirring (30 turns/
Minute) dissolving 1-2min, activated carbon decolorizing, suction filtration；
(2) step (1) filtrate is down to -2 DEG C with every 10 minutes 3 DEG C of speed, precooling is added dropwise with 1.0mL/min speed
1000ml solvent Cs, continuation -10 DEG C of crystallizations are cooled to every 10 minutes 1 DEG C of speed；
(3) insulated and stirred is complete to crystallization, and growing the grain 2h, suction filtration, washing, 40 DEG C of dryings obtain white crystalline powder.
The solvent screening experimental result of table 1
Inventor is screened during solvent screening to most of organic solvents, different combination crystallization effects
Difference, only enumerates the data of part screening test herein.
Inventor is surprisingly had found in process of the test in tetramethylethylenediamine/water mixed solvent system dissolving olaparib
Crude product, and tetramethylethylenediamine crystallization is used, effect is more preferable relative to other alone dicyandiamide solutions.Then further to tetramethyl second
The ratio of the mixed solvent of diamines/water is screened, and is found when the volume ratio of tetramethylethylenediamine/water is 25:1.0~1.2
When, effect is best, and not only purity is high, high income, and surprisingly finds that its dissolubility is significantly improved by experiment.Therefore most
Determine selection with tetramethylethylenediamine/water 25 eventually:1.0~1.2 be dissolution solvent, plus tetramethylethylenediamine crystallization, to do into one
Step screening.
Experimental example 2：Crystallization trial conditional filtering
(1) olaparib crude product 100g is taken, the mixed solution of tetramethylethylenediamine/water, heating stirring dissolving 1- is added
2min, activated carbon decolorizing, suction filtration；
(2) step (1) filtrate is down to -2 DEG C, the tetramethylethylenediamine of precooling is added dropwise, continue the crystallization that cools；
(3) insulated and stirred is complete to crystallization, growing the grain, and suction filtration is washed, and is dried, is obtained white crystalline powder.
Table 2-1 crystallization trial conditional filtering results
Table 2-2 crystallization trial conditional filtering results
Table 2-3 crystallization trial conditional filtering results
Table 2-4 crystallization trial conditional filtering results
Screening test on crystallization trial condition is extremely complex, and we only enumerate A partial experiment knot therein herein
Really.There is too many variable, the change of each technological parameter in the crystallization process that can be seen that crystal from above-mentioned result of the test
May all influence be produced on result.Inventor passes through lot of experiments, the technique that technical solution of the present invention is finally determined.
Experimental example 3：Solubility test
Trial target：Sample prepared by 1-6 of the embodiment of the present invention；
Reference substance 1：The olaparib crystal formation I prepared with reference to the A embodiments 1,2 of patent CN 105439961.
Reference substance 2：The olaparib crystal formation prepared with reference to patent CN 105254572A embodiments 1-3.
Reference substance 3：The olaparib crystal formation A prepared with reference to patent 101528714A embodiments 1,3,5.
Reference substance 4：The olaparib crystal formation L prepared with reference to patent CN101821242A embodiments 1-5.
Reference substance 5：The olaparib monohydrate crystal form compound prepared with reference to patent CN106554315A embodiments 1.
Reference substance 6：The olaparib prepared with reference to the A embodiments 1-4 of patent CN 105985294.
Reference substance 7：The olaparib prepared with reference to the A embodiments 1-4 of patent CN 105061328.
Reference substance 8：The olaparib prepared with reference to the A embodiments one, two, three of patent CN 105085407.
Reference substance 9：The olaparib prepared with reference to the A embodiments 1-4 of patent CN 105503739.
Reference substance 10：The olaparib prepared with reference to patent CN 105820126 A embodiments 4-1,4-2,4-3.
Reference substance 11：Reference literature J.Am.Chem.Soc.2014, olaparib made from 136,6142-6147.
Reference substance 12：Reference literature J.Med.Chem., 2008,51：Olaparib made from 6581-6591.
Reference substance 13：With reference to Nanjing University of Technology's Master's thesis in 2012《Olaparib and the like study on the synthesis》Report
Olaparib made from the method in road.
Above-mentioned reference substance is to test obtained crystal formation by being repeated several times, and repeatedly progress X-ray powder diffraction detection,
Treat that stable crystal form (testing result is basically identical) can (such as former patent discloses accompanying drawing, then will determine figure therewith as reference substance
Contrast, basically identical to be used as reference substance).
Its dissolubility, method are determined with reference to Chinese Pharmacopoeia two notes on the use of version in 2015：Take this product appropriate, be separately added into water,
Every strength shaking in 5 minutes 30 seconds, the dissolving situation in 30 minutes is observed, produces, the results are shown in Table 3.
Crystal formation and reference substance the dissolubility test result in water of the present invention of table 3
Above-described embodiment 1-6 aqueous samples dissolved are stirred 72 hours in 25 DEG C of constant temperature, 5ml is sampled.Sample is passed through
0.45 μm of filtering with microporous membrane, discards primary filtrate, and it is solubility (mg/ml) in water to take the μ L of subsequent filtrate 20 to determine medicament contg.
It the results are shown in Table 4：
Solubility of the crystal formation of the present invention of table 4 with prior art crystal formation in water is contrasted
As can be seen from the above table, at 25 DEG C, the solubility and prior art in water of olaparib novel crystal forms of the present invention
Compare, be significantly increased, achieve unexpected technique effect.
Experimental example 4：Stability test
Experimental example investigates the stability for the olaparib crystallization that the present invention is provided by accelerated test and long term test.
1st, accelerated test
Sample prepared by Example 1-3, is placed 6 months under conditions of 40 ± 2 DEG C of temperature, relative humidity 75 ± 5%,
Respectively at 0,1,2,3,6 the end of month character, relevant material, content is measured by sampling, the results are shown in Table 5.
Table 5：Accelerated test result (40 ± 2 DEG C of temperature, relative humidity 75 ± 5%)
As seen from Table 5, olaparib crystallization of the present invention is placed under conditions of 40 ± 2 DEG C of temperature, relative humidity 75 ± 5%
6 months, relevant content of material did not had significantly raised, and each index has no significant change, and water content is stable (3 molecular water), from another
The water that aspect demonstrates in the compound is that the crystallization water is not absorption water.
2nd, long term test
Sample prepared by Example 1-3, is placed 6 months under conditions of 25 ± 2 DEG C of temperature, relative humidity 60 ± 5%,
Respectively at 0,3,6,9,12,18,24 the end of month character, relevant material, content is measured by sampling, the results are shown in Table 6.
Table 6：Long-term test results (25 ± 2 DEG C of temperature, relative humidity 60 ± 5%)
As seen from Table 6, olaparib crystallization of the present invention is placed under conditions of 25 ± 2 DEG C of temperature, relative humidity 60 ± 5%
24 months stable, and each index has no significant change, and water content is stable (3 molecular water), demonstrates from another point of view in the compound
Water be the crystallization water be not absorption water.
Other embodiment accelerates consistent with long term test testing result.
Experimental example 5：Capsule dissolution rate is detected
Capsule is prepared with reference to the prescription and technique of patent CN106551916A embodiments 1, except that selection is different
Crystal-form compound, capsule is prepared respectively, dissolution rate detection is carried out to obtained capsule, 7 are the results are shown in Table.
Elution test method：Using basket method, under 37 DEG C and 100rpm mixing speeds, the 0.3%SDS for being placed in 900ml is molten
In liquid.After 90 min, 1ml samples are taken, and olaparib content is detected by HPLC.
The dissolution rate testing result of table 7
| Sample | Dissolution (%) | Sample | Dissolution (%) |
| Capsule made from the crystal formation of embodiment 1 | 99.2 | Capsule made from the crystal formation of reference substance 5 | 97.8 |
| Capsule made from the crystal formation of embodiment 2 | 99.3 | Capsule made from the crystal formation of reference substance 6 | 98.0 |
| Capsule made from the crystal formation of embodiment 3 | 99.3 | Capsule made from the crystal formation of reference substance 7 | 98.1 |
| Capsule made from the crystal formation of embodiment 4 | 99.4 | Capsule made from the crystal formation of reference substance 8 | 98.0 |
| Capsule made from the crystal formation of embodiment 5 | 99.3 | Capsule made from the crystal formation of reference substance 9 | 97.7 |
| Capsule made from the crystal formation of embodiment 6 | 99.1 | Capsule made from the crystal formation of reference substance 10 | 97.9 |
| Capsule made from the crystal formation of reference substance 1 | 98.1 | Capsule made from the crystal formation of reference substance 11 | 98.6 |
| Capsule made from the crystal formation of reference substance 2 | 97.5 | Capsule made from the crystal formation of reference substance 12 | 98.0 |
| Capsule made from the crystal formation of reference substance 3 | 97.2 | Capsule made from the crystal formation of reference substance 13 | 98.1 |
| Capsule made from the crystal formation of reference substance 4 | 98.2 |
Using capsule made from crystal formation of the present invention than capsule made from existing crystal formation it can be seen from above-mentioned testing result
Agent dissolution rate is significantly improved.
Claims (10)
1. a kind of drug hydrate for the treatment of cancer, it is characterised in that described hydrate is olaparib trihydrate, its point
Minor is：C24H23FN4O3·3H2O, its X-ray powder diffraction collection represented with the 2 θ ± 0.2 ° angles of diffraction 6.3928 °,
6.9115°、12.6931°、15.1126°、15.9045°、17.7123°、19.2086°、19.7743°、20.2325°、
Characteristic diffraction peak is shown at 21.0346 °, 22.2218 °, 29.0633 °, 30.4218 °.
2. a kind of drug hydrate for the treatment of cancer as claimed in claim 1, it is characterised in that measured using Cu-K alpha rays
Obtained X-ray powder diffraction figure is as shown in Figure 1.
3. a kind of preparation method of the drug hydrate for the treatment of cancer as claimed in claim 1 or 2, it is characterised in that including such as
Lower step：
(1) olaparib crude product is taken, the mixed solution of tetramethylethylenediamine/water, heating stirring dissolving 1-2min, activated carbon is added
Decolourize, suction filtration；
(2) step (1) filtrate is down to -2 DEG C, the tetramethylethylenediamine of precooling is added dropwise, continue the crystallization that cools；
(3) insulated and stirred is complete to crystallization, growing the grain, and suction filtration is washed, and is dried, is obtained white crystalline powder.
4. a kind of preparation method of the drug hydrate for the treatment of cancer as claimed in claim 3, it is characterised in that step (1)
In described tetramethylethylenediamine/water mixed solution, the volume ratio of tetramethylethylenediamine and water is 25:1.0~1.2；Step (1)
The mass volume ratio of the olaparib crude product and mixed solution is 1g:10ml~12ml；Described mixing speed is 30-50
Rev/min.
5. a kind of preparation method of the drug hydrate for the treatment of cancer as claimed in claim 4, it is characterised in that step (1)
In described tetramethylethylenediamine/water mixed solution, the volume ratio of tetramethylethylenediamine and water is 25:1.1；Step (1) is described
The mass volume ratio of olaparib crude product and mixed solution is 1g:11ml；Described mixing speed is 40 revs/min.
6. a kind of preparation method of the drug hydrate for the treatment of cancer as claimed in claim 4, it is characterised in that step (2)
The volume ratio 0.5~1 of the tetramethylethylenediamine and step (1) mixed solution:1；Step (2) described rate of addition be 1.0~
2.0mL/min, cooling extent be every 10 minutes 1 DEG C~3 DEG C；Step (2) the cooling crystallization is to be cooled to -10 DEG C~-8 DEG C analysis
It is brilliant.
7. a kind of preparation method of the drug hydrate for the treatment of cancer as claimed in claim 4, it is characterised in that step (2)
The volume ratio 0.8 of the tetramethylethylenediamine and step (1) mixed solution:1；Step (2) described rate of addition is 1.5mL/
Min, cooling extent be every 10 minutes 2 DEG C；Step (2) the cooling crystallization is to be cooled to -9 DEG C of crystallizations.
8. a kind of preparation method of the drug hydrate for the treatment of cancer as claimed in claim 4, it is characterised in that step (3)
The rearing crystal time is 1h~3h；Step (3) described drying temperature is 40 DEG C~50 DEG C.
9. a kind of preparation method of the drug hydrate for the treatment of cancer as claimed in claim 8, it is characterised in that step (3)
The rearing crystal time is 2h；Step (3) described drying temperature is 45 DEG C.
10. a kind of pharmaceutical composition of the drug hydrate containing a kind of any described treating cancer of claim 1~2, its
It is characterised by, described pharmaceutical composition is the capsule containing olaparib trihydrate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710424797.1A CN107235914A (en) | 2017-06-07 | 2017-06-07 | A kind of drug hydrate for the treatment of cancer and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710424797.1A CN107235914A (en) | 2017-06-07 | 2017-06-07 | A kind of drug hydrate for the treatment of cancer and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107235914A true CN107235914A (en) | 2017-10-10 |
Family
ID=59986055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710424797.1A Withdrawn CN107235914A (en) | 2017-06-07 | 2017-06-07 | A kind of drug hydrate for the treatment of cancer and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107235914A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107162985A (en) * | 2017-06-05 | 2017-09-15 | 山东裕欣药业有限公司 | A kind of olaparib compound and preparation method thereof |
| US10662178B2 (en) | 2018-01-31 | 2020-05-26 | Apotex Inc. | Crystalline form of Olaparib |
-
2017
- 2017-06-07 CN CN201710424797.1A patent/CN107235914A/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107162985A (en) * | 2017-06-05 | 2017-09-15 | 山东裕欣药业有限公司 | A kind of olaparib compound and preparation method thereof |
| US10662178B2 (en) | 2018-01-31 | 2020-05-26 | Apotex Inc. | Crystalline form of Olaparib |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2017107985A1 (en) | Crystals of quinazoline derivative and preparation method therefor | |
| CN107235914A (en) | A kind of drug hydrate for the treatment of cancer and preparation method thereof | |
| CN107056712A (en) | A kind of antineoplastic hydrate and preparation method thereof | |
| CN107162985A (en) | A kind of olaparib compound and preparation method thereof | |
| CN107098862A (en) | A kind of olaparib dihydrate and preparation method thereof | |
| CN106966944A (en) | A kind of vildagliptin crystal-form compound and preparation method thereof | |
| WO2023045360A1 (en) | Crystal form of macrocyclic compound, and preparation method therefor and use thereof | |
| CN106892900A (en) | A kind of Vonoprazan fumarate and preparation method thereof | |
| CN113444073A (en) | Crystal form III of morpholinyl quinazoline compound, preparation method and application thereof | |
| CN106589022B (en) | A kind of roxithromycin compound and preparation method thereof, pharmaceutical composition | |
| CN107118153A (en) | A kind of Rui Gefeini monohydrate crystal forms and preparation method thereof | |
| CN105646520A (en) | Stable Halaven compound | |
| CN106478598B (en) | A kind of Vande Thani hydrate crystal and preparation method thereof | |
| CN106083739B (en) | New gefitinib crystal form and its preparation method based on super-critical anti-solvent technology | |
| WO2017107986A1 (en) | Crystals of quinazoline derivative and preparation method therefor | |
| CN106543105B (en) | A kind of cariprazine hydrochloride crystal form IV and preparation method thereof | |
| CN106748996A (en) | A kind of Sorafenib Tosylate crystal-form compound and preparation method thereof | |
| CN107056721B (en) | A kind of Parecoxib Sodium crystalline compounds and preparation method thereof | |
| CN110036003A (en) | Novel crystal forms of AP26113 and preparation method thereof | |
| CN114174264A (en) | Crystal form XI of varlitinib mesylate and preparation method thereof | |
| CN107163025A (en) | It is a kind of to treat medical compounds of disease of digestive system and preparation method thereof | |
| CN107778187A (en) | A kind of dezocine crystal formation A and preparation method thereof | |
| CN107266389A (en) | It is a kind of to treat medicine times semihydrate of enterogastric diseases and preparation method thereof | |
| CN105777651A (en) | Crystal form of poly adenosinediphosphate-ribose polymerase (PARP) inhibitor, preparation method for crystal form and medicinal use of crystal form | |
| CN106397401B (en) | A kind of crystalline compounds of anticancer drug and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20171010 |
|
| WW01 | Invention patent application withdrawn after publication |